Establishment of four new mesothelioma cell lines: Characterization by ultrastructural and immunophenotypic analysis

European Respiratory Journal

Volumn 13, Issue 3, 1999, Pages 527-534

  Orengo, A M ^a   Spoletini, L ^b   Procopio, A ^b   Favoni, R E ^c   De Cupis, A ^c   Ardizzoni, A ^c   Castagneto, B ^d   Ribotta, M ^f   Betta, P G ^f   Ferrini, S ^a   Mutti, L ^e  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Casale Monferrato Hospital   (Italy)

^e IRCCS   (Italy)

^f NONE

Author keywords

Cell lines; Mesothelioma

Indexed keywords

ASBESTOS; CYTOKERATIN; HLA ANTIGEN CLASS 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TRANSFORMING GROWTH FACTOR; VIMENTIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CELL ULTRASTRUCTURE; CYTOGENETICS; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HAMSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MESOTHELIOMA; PHENOTYPE; PLEURA EFFUSION; PRIORITY JOURNAL; SIMIAN VIRUS 40;

EID: 0032904576     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.99.13352799     Document Type: Article

References (37)

1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-539.
2. Sugarbaker DJ, Norberto J. Multimodality management of malignant pleural mesothelioma. Chest 1998; 113: 61s-65s.
3. De Luca A, Baldi A, Esposito V, et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesothelioma. Nature Med 1997; 8: 913-916.
4. Carbone M, Rizzo P, Grimley PM, et al. Simian Virus-40 large T antigen binds p53 in human mesotheliomas. Nature Med 1997; 8: 908-912.
5. Cicala C, Pompetti F, Carbone M. SV40 induces mesothelioma in hamsters. Am J Pathol 1993; 142: 1524-1533.
6. Versnel MA, Bouts MJ, Hoogsteden HC, van der Kwast TH, Delahaye M, Hagemeijer A. Establishment of human malignant mesothelioma cell lines. Int J Cancer 1989; 44: 256-260.
7. Mannings LS, Whithaker D, Murch AR, et al. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 1991; 47: 285-290.
8. Pass HI, Stevens EJ, Oie H, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995; 59: 835-844.
9. Magnani C, Terracini B, Ivaldi C, Botta M, Mancini A, Andrion A. Pleural malignant mesothelioma and non-occupational exposure to asbestos in Casale Monferrato, Italy. Occup Environ Med 1995; 52: 362-367.
10. An International System for Human Cytogenetic Nomenclature. Mitelman F, ed. Basel, Karger, 1995.
11. Donna A, Betta PG, Chiodera P, et al. Newly marketed tissue marker for malignant mesothelioma. Immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so called antimesothelioma antibodies. Hum Pathol 1997; 28: 993-995.
12. Knuutila S, Tiainen M, Tammilheto L, Rautonen L, Pyrhonen S, Mattson K. Cytogenetics of human malignant mesothelioma. Eur Respir Rev 1993; 3: 25-28.
13. Mor O, Yaron P, Huszar M, et al. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997; 16: 9-13.
14. Bjorkqwist AM, Tammilehto L, Antilla S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997; 75: 523-527.
15. Meloni AM, Stephenson CF, Li FP, Sandberg AA. Del (6q) as a possible primary change in malignant mesothelioma. Cancer Genet Cytogenetic 1992; 59: 57-61.
16. Bell DW, Jhanwar SC, Testa JR. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 1997; 57: 4057-4062.
17. Cooke IE, Shelling AN, Le Meuth VG, Charnock FML, Ganesan TS. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chrom Cancer 1996; 15: 223-233.
18. Menasce LP, Orphanos V, Santibanez-Koref M, Boyle JM, Harrison CJ. Common region of deletion on the long arm of chromosome 6 in Non-Hodgkin's lymphoma and acute lymphoblastic leukaemia. Genes Chrom Cancer 1994; 10: 286-288.
19. Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 1991; 51: 5449-5553.
20. Trent J, Stanbridge E, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 1990; 247: 568-571.
21. Banga SS, Kim S, Hubbard K, et al. SEN6, a locus for SV40-mediated immortalization of human cells, maps to 6q26-27. Oncogens 1997; 14: 313-321.
22. Kawakami T, Furukawa Y, Sudo K, et al. Isolation and mapping of a human gene (PDCD2) that is highly homologous to Rp8, a rat gene associated with programmed cell death. Cytogenet Cell Genet 1995; 71: 41-43.
23. Carbone M, Pass HI, Rizzo P, et al. SV40 virus-like DNA sequences in human pleural mesothelioma. Oncogene 1994; 9: 1781-1790.
24. Levresse V, Moritz S, Renier A, et al. Effects of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents. Oncogene 1998; 16: 1041-1053.
25. Bright RK, Shearer MH, Kennedy RC. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell mediated cytotoxicity against simian virus transformed cells: an antibody based mechanism for tumor immunity. J Immunol 1994; 153: 2064-2071.
26. Mutti L, Valle MT, Balbi B, et al. Primary human mesothelioma cells express class II MHC, ICAM1, and B72 and can present recall antigens to autologous blood lymphocytes. Int J Cancer 1998; 78: 740-749.
27. Garlepp MJ, Leong CG. Biological and immunological aspects of malignant mesothelioma. Eur Respir J 1995; 8: 643-650.
28. Leong CC, Marley JV, Loh S, Robinson BW, Garlepp MJ. The induction of immune response to murine malignant mesothelioma by IL2 gene transfer. Immunol Cell Biol 1997; 75: 356-359.
29. Ruscetti FW, Palladino MA. Transforming growth factor-beta and the immune system. Prog Growth Factor Res 1991; 3: 159-171.
30. 2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997; 57: 3200-3207.
31. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Patho- and immunobiology of malignant mesothelioma: characterization of tumor infiltrating leukocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994; 39: 347-359.
32. Jamicki AG, Fitzpatrick DR, Robinson BW, Bielefeldt-Ohmann H. Altered CD3 chain and cytokines gene expression in tumor infiltrating T-lymphocytes during the development of mesothelioma. Cancer Lett 1996; 103: 1-9.
33. Blay JY, Negrier S, Combaret V, et al. Serum levels of interleukin 6 as a prognosis factor in metastatic renal carcinoma. Cancer Res 1992; 52: 3317-3322.
34. Zeng L, Buard A, Monnet I, Jaurand MC. In vitro effects of recombinant human interferon gamma on human mesotheliolma cell lines. Int J Cancer 1993; 55: 515-520.
35. Nakano T, Chaininan AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998; 77: 907-912.
36. Bielefeldt-Ohmann H, Marzo A, Himbeck RP, Jarnicki AG, Robinson BW, Fitzpatrick DR. Interleukin 6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 1995; 40: 241-250.
37. Bowman RV, Manning LS, Davis MR, Robinson BW. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother Pharmacol 1991; 28: 420-426.